RN
RNAZ.US Transcode Therapeutics Inc
- Market cap
- USD 22.9M
- P/E
- -
- P/B
- 2.83x
- ROE
- -445.6%
- Dividend yield
- 7,044.87%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RNAZ.US undervalued?
Graham numberThe Graham number of Transcode Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Transcode Therapeutics Inc fundamental analysis
No fundamental analysis for Transcode Therapeutics Inc yet.
Transcode Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colo…
Full company profileTranscode Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Transcode Therapeutics Inc annual financial statements
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | - | - | - | -42.5K | -98.6K | -517K | -535K | -114K | - |
| Operating Income | -384K | -457K | -727K | -6.15M | -18.7M | -19.4M | -15.7M | -28.0M | - |
| EBITDA | -69.4K | -450K | -1.95M | -6.71M | -17.5M | -18.0M | -16.2M | -34.3M | - |
| Net Income | -453K | -607K | -2.34M | -6.84M | -17.6M | -18.5M | -16.8M | -34.7M | -143B |
| EPS | -2,362 | -95 | -294 | -424 | -1,083 | -3,419 | -47 | -50 | -12,489 |
| Balance Sheet | |||||||||
| Total Assets | 215K | 217K | 1.06M | 22.9M | 7.59M | 5.17M | 7.29M | 162M | 44.7B |
| Total Liabilities | 719K | 1.31M | 4.46M | 2.53M | 4.35M | 3.53M | 9.31M | 152M | 12.6B |
| Shareholders' Equity | -504K | -1.10M | -3.41M | 20.4M | 3.24M | 1.64M | -2.02M | 10.3M | 32.1B |
| Cash & Short-term Investments | 213K | 204K | 828K | 20.8M | 4.97M | 2.77M | 5.81M | 17.8M | 4.64B |
| Total Debt | 472K | 928K | 2.09M | - | - | 451K | 38.3K | - | 3.11B |
| Cash Flow | |||||||||
| Operating Cash Flow | -300K | -509K | -493K | -5.27M | -15.8M | -18.1M | -13.3M | -19.5M | -24.1B |
| Capital Expenditure | 255K | 255K | 255K | 255K | 101K | 35.6K | 21.8K | 6.66K | 8.00 |
| Free Cash Flow | -300K | -509K | -493K | -5.52M | -15.9M | -18.1M | -13.4M | -19.5M | -24.1B |
| Ratios | |||||||||
| ROE | - | - | - | -33.5% | -542.0% | -1,130.3% | - | -335.4% | -445.6% |
| ROA | -211.3% | -280.2% | -222.1% | -29.8% | -231.5% | -358.7% | -229.7% | -21.3% | -320.0% |
| Debt to Equity | - | - | - | - | - | 0.27x | - | - | 0.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Transcode Therapeutics Inc dividends
- Dividend yield
- 7,044.87%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 1.61B | 2,335 | - |
| 2024 | USD 30.6M | 86 | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:28 on May 15, 2025.
Who owns Transcode Therapeutics Inc
- Insiders 1.78%
- Institutions 0.82%
- Public & others 97.40%
- Shares outstanding 16.9M
- Free float 2.15M
Top funds holding RNAZ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 5.09K | 0.03% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 1.18K | 0.01% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 510.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding RNAZ.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Yorkville Advisors Global, LP | 19.6K | 0.12% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.55K | 0.04% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 2.98K | 0.02% | 0.00% | Jun 2026 |
| UBS Group AG | 2.89K | 0.02% | -65.18% | Jun 2026 |
| Mercer Global Advisors Inc. | 1.54K | 0.01% | 0.00% | Jun 2026 |
| FMR Inc | 706.00 | 0.00% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 677.00 | 0.00% | +196.93% | Jun 2026 |
| Wells Fargo & Co | 55.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 12.00 | 0.00% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Transcode Therapeutics Inc company profile
- Company name
- Transcode Therapeutics Inc
- Ticker
- RNAZ.US
- Exchange
- USA Stocks
- Listed since
- Jul 8, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Fiscal year end
- December
- Address
- 6 Liberty Square, Boston, MA, United States, 02109
- Phone
- 857 837 3099
- Website
- transcodetherapeutics.com
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Transcode Therapeutics Inc management
6- Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D.CEO & Executive Chairman of the Board · born 1959
- Dr. Zdravka Medarova Ph.D.Scientific Co-Founder & Chief Scientific Officer · born 1975
- Dr. Anna Moore Ph.D.Scientific Co-Founder, Scientific Advisor & Chair of Scientific Advisory Board · born 1962
- Mr. John A. Tattory CPAInterim Chief Financial Officer · born 1966
- Dr. Daniel R. Vlock M.D.Chief Medical Officer · born 1952
- Dr. Michel Janicot PH.D.Consulting Head of Translational Science